Clinical Trial

Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases

Study acronym: HAITILS-PHP
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 15, 2023 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
Evaluate the safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion and preconditioning with percutaneous hepatic perfusion in patients with liver metastases (but not restricted to) of malignant melanoma
Trial Details
NCT Number NCT05903937
Lead Sponsor Vastra Gotaland Region
Conditions Uveal Melanoma, Metastatic Cutaneous Melanoma
Enrollment 6 participants
Start Date 2023-12-31
Primary Completion 2024-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-06-15